AIM immunotech - duripanc primary endpoint analysis to begin December 2026; topline results expected Q1 2027
AIM immunotech - duripanc primary endpoint analysis to begin December 2026; topline results expected Q1 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.